ANTIDOTE LIMITED
Company number 04808290 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Score: C-
Explanation: Antidote Limited is like a patient who has just been discharged from intensive care. While the latest results for 2025 show a remarkable and encouraging recovery from a near-fatal financial low point in 2024, the business has suffered severe financial atrophy over the last several years. The company's overall financial mass (net assets) is a mere fraction of its historical strength, leaving it fragile and vulnerable to external shocks. The immediate vital signs are stable, but the patient has a long way to go before reaching peak physical condition.
Key Vital Signs
1. Pulse (Cash Position): * Metric: Cash increased from £1,362 (2024) to £20,640 (2025). * Interpretation: The pulse is getting stronger. In 2024, the company was running on fumes with barely enough cash to survive a minor emergency. The infusion of £20,640 in 2025 shows the business is generating lifeblood once again, though this is still drastically lower than the healthy cash reserves of £289k-£571k seen between 2016-2018.
2. Blood Pressure (Liquidity): * Metric: Current Assets (£53,040) vs. Current Liabilities (£18,106). This yields a Current Ratio of roughly 2.9:1. * Interpretation: Healthy blood pressure. The company can comfortably cover its short-term debts, which means there is no immediate risk of financial cardiac arrest. However, it is worth noting that a large portion of these current assets (£32,400) is tied up in trade debtors, meaning the cash hasn't fully entered the bloodstream yet.
3. Body Mass (Net Assets & Historical Comparison): * Metric: Net Assets increased from £1,380 (2024) to £35,572 (2025). Historically, net assets were £314k (2016), £401k (2017), £410k (2018), and £306k (2019/2020). * Interpretation: The patient has experienced dramatic weight loss over the last half-decade. While 2025 shows a much-needed gain in financial mass, the company is operating at a fraction of its historical size. The business has effectively transitioned from a robust agency to a micro-entity (with only 1 employee on average).
4. Circulation (Trade Debtors): * Metric: Trade debtors surged from £2,401 (2024) to £32,400 (2025). * Interpretation: This is the primary driver of the 2025 recovery, indicating a significant uptick in business activity. However, debtors represent blocked arteries—the cash hasn't flowed through yet. The health of this recovery depends entirely on these clients paying their invoices on time.
Diagnosis
Severe Financial Atrophy with Recent Stabilization
The financial data reveals a business that underwent a severe, multi-year contraction, likely exacerbated by the pandemic or major client losses, which saw its total assets plummet from over £1.1M in 2016 to under £9k in 2024. The year 2024 represented the critical nadir: net assets of just £1,380 and a cash balance of £1,362 indicated a business that was clinically insolvent if any unexpected bills had arrived.
However, the 2025 accounts show clear symptoms of a turnaround. The company has successfully generated new business, evidenced by the large jump in trade debtors. The business is now technically profitable and rebuilding its equity base (£35,472 in the Profit & Loss reserve, up from £1,280). The complete lack of long-term debt is a positive sign, meaning the business is not carrying a heavy financial tumor. Still, the overarching diagnosis is one of fragility; the company is in remission, but its low cash reserves and reliance on collecting trade debts mean its immune system is still compromised.
Recommendations
- Clear the Arteries (Aggressive Debt Collection): With £32,400 sitting in trade debtors against £7,851 in trade creditors, cash flow is entirely dependent on client payment. Implement strict credit control procedures to ensure this money is collected promptly. The longer it sits in debtors, the higher the risk of bad debt (clots).
- Build the Immune System (Cash Buffer): While £20k in cash is a vast improvement over £1.3k, it is insufficient for a business that historically operated with hundreds of thousands in reserves. Aim to retain profits to build a minimum of 3-6 months of operating expenses in cash to protect against future shocks.
- Maintain Leanness (Control Overheads): The company has survived by shrinking its cost base (reducing employees to 1, writing down computer assets). As business picks up, resist the urge to rapidly inflate fixed costs. Keep the business lean and agile to maintain the healthy current ratio.
- Tax Hygiene: Ensure the £3,418 owed in "other taxation and social security" is paid on time. With such thin margins for error, HMRC penalties are a complication the business cannot afford.